Article Text

PDF
Erythropoietin and retinopathy: the beginning of an understanding
  1. C J Diskin
  1. C J Diskinth, HNDT, Auburn University, Bldg 21, 121 N. 20th Street, Opelika, AL 36801, USA; HNDT512{at}bellsouth.net

Statistics from Altmetric.com

I would like to congratulate Kase and his colleagues for their work finding that erythropoietin (EPO) receptors (EPOR) are strongly expressed in the microvessels of patients with proliferative diabetic retinopathy.1 As they carefully note, while experts disagree on the use of recombinant human erythropoietin (rHuEPO) in patients with diabetes, the present work should contribute to a cautious re-evaluation of the topic.

Diabetic retinopathy often accompanies end stage renal disease (ESRD) from diabetes where rHuEPO is frequently administered. Because heparin was required as an anticoagulant, many early clinicians worried that chronic maintenance haemodialysis would worsen …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.